Bafna Pharmaceuticals
Healthcare
BAFNAPH NSE
₹438.80 +8.60 (+2.00%)
- P/E
- 133.37
Close 4 Nov 2026 ₹438.80 +272.55 +164% 1Y
Start ₹166.25
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 11.90%
- Debt to Equity
- 0.39
- EPS (TTM)
- ₹3.29
- Book Value
- ₹40.64
- Market Cap
- —
- P/E (TTM)
- 133.37
- P/B
- 10.80
- ROE
- 12.30%
- Dividend Yield
- 0.00%
- EBITDA
- ₹1.50 Cr
- 52W High
- ₹479.95
- 52W Low
- ₹94.77
- Day Range
- ₹438.80 – ₹438.80
- Volume
- 5,404
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Bafna Pharmaceuticals (this company) | ₹438.80 | 133.37 | ₹1,018 Cr | 10.80 | 0.00% | 12.30% | 11.90% | ₹143 Cr | ₹8 Cr |
| Median 8 companies | ₹1,587.70 | 58.71 | ₹1,25,337 Cr | 7.29 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
35 Poor
Data confidence 98/100
surveillance:ASM2
Category scores
- Quality
- 39
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 17
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 8
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 42
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 99
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the
fundamentals here (surveillance:ASM2 ≤ 50).
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
5- Stock is trading at 9.50 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 9.88% over last 3 years.
- Earnings include an other income of Rs.6.07 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 5 | 3 | 11 |
| Oscillators | Bullish | 2 | 3 | 4 |
| Moving Averages | Strong Bullish | 3 | 0 | 7 |
Oscillators
Bullish
Bearish
2
Neutral
3
Bullish
4
Overall
Strong Bullish
Bearish
5
Neutral
3
Bullish
11
Moving Averages
Strong Bullish
Bearish
3
Neutral
0
Bullish
7
Key readings
- RSI (14)
- 60.21
- Neutral
- MACD (12,26,9)
- 20.96
- Bearish
- SMA (50)
- 368.18
- Bullish
- SMA (200)
- 211.50
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +5.91% |
|---|---|
| 5Y | +16.29% |
| 3Y | +9.50% |
| 1Y | +3.42% |
| TTM | −3.13% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | +12.89% |
| 3Y | 0.00% |
| 1Y | +175.00% |
| TTM | −5.80% |
Operating cash flow
| 10Y | Turned positive |
|---|---|
| 5Y | Turned positive |
| 3Y | +44.22% |
| 1Y | −31.82% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +7.07 pp |
|---|---|
| 5Y | −3.48 pp |
| 3Y | −3.31 pp |
| 1Y | +3.07 pp |
| TTM | −1.95 pp |
Revenue by year
| Mar 2017 | ₹65.00 Cr |
|---|---|
| Mar 2018 | ₹46.00 Cr |
| Mar 2019 | ₹44.00 Cr |
| Mar 2020 | ₹42.00 Cr |
| Mar 2021 | ₹71.00 Cr |
| Mar 2022 | ₹85.00 Cr |
| Mar 2023 | ₹115 Cr |
| Mar 2024 | ₹152 Cr |
| Mar 2025 | ₹146 Cr |
| Mar 2026 | ₹151 Cr |
Net profit by year
| Mar 2017 | −₹18.00 Cr |
|---|---|
| Mar 2018 | −₹16.00 Cr |
| Mar 2019 | −₹20.00 Cr |
| Mar 2020 | −₹25.00 Cr |
| Mar 2021 | ₹6.00 Cr |
| Mar 2022 | ₹5.00 Cr |
| Mar 2023 | ₹11.00 Cr |
| Mar 2024 | ₹7.00 Cr |
| Mar 2025 | ₹4.00 Cr |
| Mar 2026 | ₹11.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41.95 | 40.68 | 28.44 | 41.4 | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 | 35.47 | 38.29 | 42.24 | 26.58 |
| Expenses | 35.66 | 36.67 | 30.51 | 38.51 | 32.08 | 36.53 | 30.13 | 35.95 | 29.55 | 31.19 | 35.24 | 38.69 | 25.69 |
| Operating Profit | 6.29 | 4.01 | −2.07 | 2.89 | 1.21 | 3.79 | 3.06 | 3.11 | 5.07 | 4.28 | 3.05 | 3.55 | 0.89 |
| OPM % | 14.99% | 9.86% | −7.28% | 6.98% | 3.63% | 9.4% | 9.22% | 7.96% | 14.64% | 12.07% | 7.97% | 8.4% | 3.35% |
| Other Income | 1.87 | 0.16 | 0.98 | 0.52 | 0.16 | 1.02 | 0.19 | −0.76 | 0.6 | 1.18 | 1.22 | 1.76 | 1.91 |
| Interest | 0.6 | 0.44 | 0.58 | 0.68 | 0.65 | 0.62 | 0.64 | 0.82 | 0.91 | 0.86 | 0.86 | 1.03 | 0.94 |
| Depreciation | 1.21 | 1.24 | 1.27 | 1.27 | 1.44 | 1.58 | 1.66 | 0.22 | 1.37 | 1.47 | 1.57 | 1.66 | 1.78 |
| PBT | 6.35 | 2.48 | −2.94 | 1.46 | −0.72 | 2.62 | 0.95 | 1.31 | 3.39 | 3.12 | 1.84 | 2.62 | 0.08 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | −4.96% | 0% |
| Net Profit | 6.35 | 2.48 | −2.94 | 1.46 | −0.72 | 2.62 | 0.95 | 1.31 | 3.39 | 3.12 | 1.84 | 2.75 | 0.08 |
| EPS (₹) | 2.68 | 1.05 | −1.24 | 0.62 | −0.3 | 1.11 | 0.4 | 0.55 | 1.43 | 1.32 | 0.78 | 1.16 | 0.03 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 146 | 151 | 143 |
| Expenses | 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 135 | 135 | 131 |
| Operating Profit | −16 | 3 | −5 | −35 | −13 | 1 | 10 | 12 | 16 | 11 | 11 | 16 | 12 |
| OPM % | −16% | 3.3% | −8% | −77% | −30% | 2.9% | 14% | 14% | 14% | 7% | 8% | 11% | 8% |
| Other Income | 40 | 1 | 1 | 31 | 0 | −23 | 1 | 0 | 3 | 4 | 1 | 5 | 6 |
| Interest | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 4 | 4 |
| Depreciation | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 6 | 6 |
| PBT | 6 | −13 | −19 | −14 | −18 | −25 | 6 | 5 | 12 | 7 | 4 | 11 | 8 |
| Tax % | 0% | −3% | −4% | 15% | 8% | 0% | 0% | 0% | 2% | 0% | 0% | −1% | — |
| Net Profit | 6 | −12 | −18 | −16 | −20 | −25 | 6 | 5 | 11 | 7 | 4 | 11 | 8 |
| EPS (₹) | 3.28 | −6.53 | −9.9 | −6.95 | −8.34 | −107 | 2.46 | 2.21 | 4.79 | 3.11 | 1.75 | 4.69 | 3.29 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 53 | 41 | 26 | 17 | −3 | 49 | 33 | 38 | 50 | 57 | 61 | 72 |
| Borrowings | 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 28 | 37 |
| Other Liabilities | 50 | 45 | 40 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 40 | 42 |
| Total Liabilities | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 176 |
| Fixed Assets | 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 59 | 82 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 12 | 7 | 3 |
| Investments | 18 | 18 | 18 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 87 | 91 |
| Total Assets | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 176 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 9 | −3 | 14 | −7 | −1 | −34 | −14 | 10 | 5 | 9 | 22 | 15 |
| Investing | 56 | −1 | −8 | 38 | 4 | 33 | −5 | −7 | −7 | −15 | −21 | −22 |
| Financing | −66 | 4 | −5 | −31 | −2 | 7 | 12 | −5 | 10 | −1 | 1 | 6 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 6 | −7 | −2 | 8 | −6 | 2 | −1 |
| Free Cash Flow | 2 | −5 | 20 | 40 | −1 | −36 | −20 | 2 | −2 | −6 | 0 | −10 |
| CFO/OP | −74 | −106 | −263 | 20 | 8 | −2,786 | −132 | 83 | 32 | 87 | 194 | 94 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 | 101 | 106 |
| Inventory Days | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 | 127 | 129 |
| Days Payable | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 | 140 | 139 |
| Cash Conversion Cycle | 220 | 214 | 255 | 31 | −188 | 31 | 96 | 135 | 94 | 84 | 88 | 96 |
| Working Capital Days | 56 | 125 | −36 | −108 | −210 | 89 | 121 | 123 | 104 | 92 | 74 | 74 |
| ROCE % | −13% | 0% | −6% | −35% | −21% | −3% | 10% | 11% | 16% | 9% | 8% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bafna Pharmaceuticals insights
68 extracted metrics across FY11–FY27.
Documents
- 23 Jan 2026
- 2 Apr 2025
- 5 Feb 2024
- 4 Mar 2020
- 27 Feb 2020
- General announcements 12 Oct 2026
Frequently Asked Questions about Bafna Pharmaceuticals
What does Bafna Pharmaceuticals Ltd do?
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations
Where is Bafna Pharmaceuticals Ltd (BAFNAPH) listed?
Bafna Pharmaceuticals Ltd trades as BAFNAPH on the NSE and under code 532989 on the BSE.
Which sector does Bafna Pharmaceuticals Ltd belong to?
Bafna Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd trades at a PE ratio of 133.37 as of 4 Nov 2026, on earnings per share of ₹3.29, against a book value of ₹40.64 per share.
What is the 52-week high and low of Bafna Pharmaceuticals Ltd?
Over the last 52 weeks Bafna Pharmaceuticals Ltd has traded between ₹94.77 and ₹479.95 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd reported a return on equity of 12.30%. Its debt-to-equity ratio is 0.39.
Company Information
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations
Website bafnapharma.com
CEO Mr. Bansilal Mahaveer Chand Bafna
Employees 406
Listed 27 Feb 2020
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BAFNAPH.md for Bafna Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.